At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl) May 26, 2026 09:26AM
Sun Pharma to acquire Organon for $14 per share in $11.75 billion deal Apr 26, 2026 07:51PM
Sun Pharma signs Definitive Agreement to Acquire Organon Apr 26, 2026 07:51PM
Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis Mar 16, 2026 07:00AM
Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) Jan 15, 2026 02:07PM


Oct 22, 2025 11:00AM Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America
Mar 9, 2025 10:07PM Sun Pharma to Acquire Checkpoint Therapeutics
Mar 9, 2025 10:06PM Sun Pharma to Acquire Checkpoint Therapeutics
Oct 25, 2024 08:30AM Studies Show Sun Pharma's WINLEVI® (clascoterone) Cream 1% Reduces Sebum Levels and is Suitable for Combination With Other Commonly Used Topical Acne Medications
Sep 26, 2024 08:00AM Sun Pharma Presents New Clinical Efficacy and Safety Data in Severe Dermatological Conditions at the 2024 European Academy of Dermatology and Venereology (EADV) Congress
May 30, 2023 04:56AM Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand
Jan 19, 2023 09:39AM Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Aug 31, 2021 08:05AM Sun Pharma and Cassiopea announce the expiry of the HSR Act process and the successful consummation of their Winlevi® (clascoterone cream 1%) agreement
Jul 26, 2021 03:46AM Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada
Mar 27, 2020 03:00PM Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment
Feb 10, 2020 07:45AM Sun Pharma Launches New Ad Campaign to Raise Awareness of Acne and its Impact on Everyday Life
Feb 4, 2020 05:46AM Sun Pharma Introduces ABSORICA LD™ (Isotretinoin) Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.
Oct 14, 2019 12:05AM Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.
Jul 17, 2019 07:45AM Sun Pharma Introduces Access Program for Patients Prescribed XELPROS in the U.S.
Jul 15, 2019 12:10AM Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing
Apr 8, 2019 12:05AM Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.
Sep 14, 2018 12:05AM Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension
Aug 16, 2018 12:10AM Sun Pharma Announces U.S. FDA Approval of CEQUA™ to Treat Dry Eye Disease
Aug 6, 2018 06:45AM Sun Pharma Launches Novel Drug Kapspargo Sprinkle™ in USA
Jul 11, 2018 08:07AM DUSA Pharmaceuticals, Inc. Files Lawsuit Against Biofrontera Inc. for Patent Infringement, Trade Secret Misappropriation, and Tortious Interference
May 23, 2018 12:21AM Sun Pharma Announces USFDA Approval of YONSA® (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone
Sep 20, 2017 07:27AM Sun Pharma Odomzo® (Sonidegib) New Label Approval Shows Sustained Duration of Response of 26 Months in Treatment of Locally Advanced Basal Cell Carcinoma
May 24, 2017 08:03AM Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Mar 1, 2017 10:35AM Sun Pharma Announces Data from Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting
Oct 1, 2016 05:05AM Sun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoria
Aug 8, 2016 09:00AM Sun Pharma Extends Imatinib Mesylate Savings Card Program Benefits for Patients in USA
Jul 27, 2016 01:59PM Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis